A quantitative measure of handgrip myotonia in non-dystrophic myotonia-Reference-Cited by-同舟云学术

A quantitative measure of handgrip myotonia in non-dystrophic myotonia

Published:2012-09-13 Issue:4 Volume:46 Page:482-489
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Statland Jeffrey M.,Bundy Brian N.,Wang Yunxia,Trivedi Jaya R.,Raja Rayan Dipa,Herbelin Laura,Donlan Merideth,McLin Rhonda,Eichinger Katy J.,Findlater Karen,Dewar Liz,Pandya Shree,Martens William B.,Venance Shannon L.,Matthews Emma,Amato Anthony A.,Hanna Michael G.,Griggs Robert C.,Barohn Richard J.,

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Reference28 articles.

1. Paramyotonia congenita and hyperkalemic periodic paralysis are linked to the adult muscle sodium channel gene;Ebers;Ann Neurol,1991

2. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene;Fontaine;Science,1990

3. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita);George;Nat Genet,1993

4. The skeletal muscle chloride channel in dominant and recessive human myotonia;Koch;Science,1992

5. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus;Ptacek;Am J Hum Genet,1991

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term monitoring of stimulated lower leg skeletal muscle forces compared with voluntary contractions in myopathy patients – A five-year follow-up report on 5 adults;Journal of Bodywork and Movement Therapies;2024-04

2. The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis;Science Translational Medicine;2024-03-20

3. Non‐dystrophic myotonia: 2‐year clinical and patient reported outcomes;Muscle & Nerve;2022-06-16

4. GripAble: An accurate, sensitive and robust digital device for measuring grip strength;Journal of Rehabilitation and Assistive Technologies Engineering;2022-01

5. Current Treatment Options for Patients with Myotonic Dystrophy Type 2;Current Treatment Options in Neurology;2021-09